Identifying the Potential Diagnostic Gene Biomarkers and Forecasting the Potential Therapeutic Agents for Advanced Diabetic Nephropathy Based on Pyroptosis and Ferroptosis
Open Access
- 1 August 2024
- journal article
- research article
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 17, 5763-5779
Abstract
Background: Diabetic nephropathy (DN) is a prevalent complication of diabetes, often leading to end-stage kidney disease (ESKD). Advanced DN progresses to ESKD rapidly, yet effective diagnostic indicators and treatments are lacking. Methods: Two DN-related datasets were obtained from the Gene Expression Omnibus (GEO) database. Differentially expressed genes (DEGs) were identified using the R packages. Pyroptosis-related genes (PRGs) and ferroptosis-related genes (FRGs) were collected from their respective database. Pyroptosis- and ferroptosis-related differentially expressed genes (PFRDEGs) were identified by overlapping DEGs, PRGs, and FRGs for further analysis, including functional enrichment and immune infiltration. Hub genes were identified using a PPI network via MCODE-plugin in Cytoscape. GeneMANIA was utilized to explore intermolecular interactions among hub genes. Based on these hub genes, a diagnostic model was constructed using the receiver operating characteristic curve and potential therapeutic agents were retrieved. Correlation analysis between hub genes and estimated glomerular filtration rate was performed using Nephroseq v5 database, and expression of hub genes was validated in external GEO database, Nephroseq v5 database and DN mice in vivo. Results: Four hub genes (CYBB, LCN2, JUN and ADIPOQ) were identified, and three of the four hub genes (CYBB, LCN2 and ADIPOQ) were found to be potential biomarkers for advanced DN. On this basis, three potential therapeutic agents were screened. More importantly, a series of biological experiments confirmed that CYBB and LCN2 were significantly up-regulated in DN mice. Conclusion: This study identifies three hub genes as diagnostic biomarkers and mines three potential therapeutic agents for advanced DN, providing new insights into the role of pyroptosis and ferroptosis in advanced DN and laying the foundation for future research.Keywords
This publication has 51 references indexed in Scilit:
- Pyrroloquinoline quinone ameliorates renal fibrosis in diabetic nephropathy by inhibiting the pyroptosis pathway in C57BL/6 mice and human kidney 2 cellsBiomedicine & Pharmacotherapy, 2022
- Carnosine alleviates podocyte injury in diabetic nephropathy by targeting caspase-1-mediated pyroptosisInternational Immunopharmacology, 2021
- Hirudin ameliorates diabetic nephropathy by inhibiting Gsdmd-mediated pyroptosisCell Biology and Toxicology, 2021
- IGFBP-1 expression is reduced in human type 2 diabetic glomeruli and modulates β1-integrin/FAK signalling in human podocytesDiabetologia, 2021
- Inhibition of ferroptosis by up-regulating Nrf2 delayed the progression of diabetic nephropathyFree Radical Biology and Medicine, 2021
- A novel missense mutation in the NADPH binding domain of CYBB abolishes the NADPH oxidase activity in a male patient with increased susceptibility to infectionsMicrobial Pathogenesis, 2016
- Diet-Induced Podocyte Dysfunction in Drosophila and MammalsCell Reports, 2015
- “Normoalbuminuric” diabetic nephropathy: tubular damage and NGALActa Diabetologica, 2013
- Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell DeathCell, 2012
- Normal-range albuminuria does not exclude nephropathy in diabetic childrenPediatric Nephrology, 2010